Use of sting agonists to treat chronic hepatitis B virus infection
US10045961B2 · kind B2 · utility
3Cited by
0References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 10, 2017 |
| Grant date | Aug 14, 2018 |
| Priority date | — |
| Expiry date | Apr 10, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods of treating a subject having hepatitis B viral (HBV) infection. More specifically, disclosed herein are methods of stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular agonists of STING to suppress HBV replication in hepatocytes. The methods are especially suitable for use in the treatment of chronic HBV infections. Also disclosed herein are methods of identifying compounds useful in the treatment of HBV infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.